Receptor binding and analgesic properties of oxymorphazone

Steven Galetta, Geoffrey Ling, Louis Wolfin, Gavril W. Pasternak

Research output: Contribution to journalArticle

Abstract

The 14-hydroxydihydromorphinone hydrazones have been quite useful in studying aspects of opiate receptor binding and function. The most extensively studied, naloxazone, effectively and selectively inhibits high affinity (mu1) sites in vitro and morphine analgesia in vivo. We now report on the actions of oxymorphazone on receptor binding in vitro and on analgesia in vivo. Oxymorphazone effectively lowers 3H-opioid binding despite extensive washes with the same selectively for high affinity, or mu1, binding sites as naloxazone. Acutely, oxymorphazone was less potent in vivo than oxymorphone (ED50's of 0.8 and 0.4 mg/kg, respectively). Both quantal dose response curves were parallel. At higher doses (100 mg/kg), 83% of animals given oxymorphazone over 20 hr previously were analgesic whereas none of the oxymorphone animals were (p<0.001). Oxymorphazone also produced prolonged analgesia after icv administration. These results, in addition to other studies, suggest that oxymorphazone's actions cannot be adequately explained by pharmacokinetic differences from oxymorphone and supports the hypothesis that the drug works via prolonged receptor binding.

Original languageEnglish (US)
Pages (from-to)1389-1392
Number of pages4
JournalLife Sciences
Volume31
Issue number12-13
DOIs
StatePublished - Jan 1 1982
Externally publishedYes

Fingerprint

Analgesics
Oxymorphone
Analgesia
Animals
Pharmacokinetics
Opioid Receptors
Morphine
Opioid Analgesics
oxymorphazone
Binding Sites
Pharmaceutical Preparations
In Vitro Techniques
naloxazone

ASJC Scopus subject areas

  • Pharmacology

Cite this

Galetta, S., Ling, G., Wolfin, L., & Pasternak, G. W. (1982). Receptor binding and analgesic properties of oxymorphazone. Life Sciences, 31(12-13), 1389-1392. https://doi.org/10.1016/0024-3205(82)90388-5

Receptor binding and analgesic properties of oxymorphazone. / Galetta, Steven; Ling, Geoffrey; Wolfin, Louis; Pasternak, Gavril W.

In: Life Sciences, Vol. 31, No. 12-13, 01.01.1982, p. 1389-1392.

Research output: Contribution to journalArticle

Galetta, S, Ling, G, Wolfin, L & Pasternak, GW 1982, 'Receptor binding and analgesic properties of oxymorphazone', Life Sciences, vol. 31, no. 12-13, pp. 1389-1392. https://doi.org/10.1016/0024-3205(82)90388-5
Galetta S, Ling G, Wolfin L, Pasternak GW. Receptor binding and analgesic properties of oxymorphazone. Life Sciences. 1982 Jan 1;31(12-13):1389-1392. https://doi.org/10.1016/0024-3205(82)90388-5
Galetta, Steven ; Ling, Geoffrey ; Wolfin, Louis ; Pasternak, Gavril W. / Receptor binding and analgesic properties of oxymorphazone. In: Life Sciences. 1982 ; Vol. 31, No. 12-13. pp. 1389-1392.
@article{fae94c187d4149639f80998044e5d968,
title = "Receptor binding and analgesic properties of oxymorphazone",
abstract = "The 14-hydroxydihydromorphinone hydrazones have been quite useful in studying aspects of opiate receptor binding and function. The most extensively studied, naloxazone, effectively and selectively inhibits high affinity (mu1) sites in vitro and morphine analgesia in vivo. We now report on the actions of oxymorphazone on receptor binding in vitro and on analgesia in vivo. Oxymorphazone effectively lowers 3H-opioid binding despite extensive washes with the same selectively for high affinity, or mu1, binding sites as naloxazone. Acutely, oxymorphazone was less potent in vivo than oxymorphone (ED50's of 0.8 and 0.4 mg/kg, respectively). Both quantal dose response curves were parallel. At higher doses (100 mg/kg), 83{\%} of animals given oxymorphazone over 20 hr previously were analgesic whereas none of the oxymorphone animals were (p<0.001). Oxymorphazone also produced prolonged analgesia after icv administration. These results, in addition to other studies, suggest that oxymorphazone's actions cannot be adequately explained by pharmacokinetic differences from oxymorphone and supports the hypothesis that the drug works via prolonged receptor binding.",
author = "Steven Galetta and Geoffrey Ling and Louis Wolfin and Pasternak, {Gavril W.}",
year = "1982",
month = "1",
day = "1",
doi = "10.1016/0024-3205(82)90388-5",
language = "English (US)",
volume = "31",
pages = "1389--1392",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "12-13",

}

TY - JOUR

T1 - Receptor binding and analgesic properties of oxymorphazone

AU - Galetta, Steven

AU - Ling, Geoffrey

AU - Wolfin, Louis

AU - Pasternak, Gavril W.

PY - 1982/1/1

Y1 - 1982/1/1

N2 - The 14-hydroxydihydromorphinone hydrazones have been quite useful in studying aspects of opiate receptor binding and function. The most extensively studied, naloxazone, effectively and selectively inhibits high affinity (mu1) sites in vitro and morphine analgesia in vivo. We now report on the actions of oxymorphazone on receptor binding in vitro and on analgesia in vivo. Oxymorphazone effectively lowers 3H-opioid binding despite extensive washes with the same selectively for high affinity, or mu1, binding sites as naloxazone. Acutely, oxymorphazone was less potent in vivo than oxymorphone (ED50's of 0.8 and 0.4 mg/kg, respectively). Both quantal dose response curves were parallel. At higher doses (100 mg/kg), 83% of animals given oxymorphazone over 20 hr previously were analgesic whereas none of the oxymorphone animals were (p<0.001). Oxymorphazone also produced prolonged analgesia after icv administration. These results, in addition to other studies, suggest that oxymorphazone's actions cannot be adequately explained by pharmacokinetic differences from oxymorphone and supports the hypothesis that the drug works via prolonged receptor binding.

AB - The 14-hydroxydihydromorphinone hydrazones have been quite useful in studying aspects of opiate receptor binding and function. The most extensively studied, naloxazone, effectively and selectively inhibits high affinity (mu1) sites in vitro and morphine analgesia in vivo. We now report on the actions of oxymorphazone on receptor binding in vitro and on analgesia in vivo. Oxymorphazone effectively lowers 3H-opioid binding despite extensive washes with the same selectively for high affinity, or mu1, binding sites as naloxazone. Acutely, oxymorphazone was less potent in vivo than oxymorphone (ED50's of 0.8 and 0.4 mg/kg, respectively). Both quantal dose response curves were parallel. At higher doses (100 mg/kg), 83% of animals given oxymorphazone over 20 hr previously were analgesic whereas none of the oxymorphone animals were (p<0.001). Oxymorphazone also produced prolonged analgesia after icv administration. These results, in addition to other studies, suggest that oxymorphazone's actions cannot be adequately explained by pharmacokinetic differences from oxymorphone and supports the hypothesis that the drug works via prolonged receptor binding.

UR - http://www.scopus.com/inward/record.url?scp=0020355857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020355857&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(82)90388-5

DO - 10.1016/0024-3205(82)90388-5

M3 - Article

C2 - 6183551

AN - SCOPUS:0020355857

VL - 31

SP - 1389

EP - 1392

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 12-13

ER -